46 citations
,
May 2021 in “Stem Cell Research & Therapy” Strontium ranelate helps cartilage growth by blocking a specific cell pathway.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
4 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings”
3 citations
,
January 2024 in “Liver International” Targeting thyroid hormone receptor α in liver cells may help treat liver fibrosis.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine” 2 citations
,
September 1993 in “PubMed” Levothyroxine treatment fully cured the young man's hypothyroid symptoms.
60 citations
,
November 2020 in “International Journal of Medical Sciences” NIR light therapy may effectively treat eye diseases and improve brain function without side effects.
September 2023 in “Journal of the American Academy of Dermatology” Children with alopecia areata, especially with Down syndrome or thyroid issues, should be screened for thyroid disease.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
16 citations
,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
19 citations
,
December 2016 in “The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics” Certain drugs increase calcium levels in cancer cells by triggering internal calcium release.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Frequent blood transfusions in beta thalassemia patients can lead to thyroid problems.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
July 2008 in “Biomedical Imaging and Intervention Journal” New cancer treatments are more precise and less toxic, improving survival rates, but Asia faces challenges in adopting these advancements.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
15 citations
,
May 1987 in “Fundamental and applied toxicology” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
9 citations
,
October 1982 in “PubMed” November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
24 citations
,
September 2014 in “PloS one” Thyroid hormone receptors are essential for hair growth and wound healing.
11 citations
,
April 2021 in “Journal of Clinical Medicine” The LED device safely improves neck skin appearance without affecting thyroid function.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
1 citations
,
March 2015 in “Journal of Cutaneous Medicine and Surgery” Eyebrow hair transplants can regrow after high-dose radiation therapy.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.